Cosmo Bio Company,Limited
3386.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.82 | -0.54 | -0.01 | 0.28 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 67.33 | 42.72 | 13.02 | -240.41 |
| Quality | ||||
| ROIC | 0.00% | 0.01% | 1.82% | -0.22% |
| Gross Margin | 35.08% | 34.95% | 34.24% | 32.65% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 4.16% | 3.61% | 11.90% | 31.22% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -34.72 | -33.02 | -5.22 | 148.31 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.54 | 1.51 | 2.03 | 1.66 |
| Cash Conversion Cycle | 122.93 | 128.36 | 111.38 | 118.98 |